Core Viewpoint - The company expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of Zewokaiolun Injection and the acceptance of the NDA for Shurukiaolun Injection by the NMPA [1] Financial Performance - The net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zewokaiolun Injection in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in R&D expenses for both Zewokaiolun Injection and Shurukiaolun Injection [1]
科济药业-B发盈警 预期2025年取得净亏损同比减少至不超过约1.2亿元